Back to search

Article

Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment

2022-02-25

Abstract excerpt

<h4>ABSTRACT</h4> Neoadjuvant chemotherapy (NACT) used for triple negative breast cancer (TNBC) eradicates tumors in approximately 45% of patients. Unfortunately, TNBC patients with substantial residual cancer burden have poor metastasis free and overall survival rates. We previously demonstrated mitochondrial oxidative phosphorylation (OXPHOS) was elevated and was a unique therapeutic dependency of residual TNBC...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
93f36d0b-5142-5b6a-b3d2-841ea13bc927
DOI
10.1101/2022.02.25.481996
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatmentDOI 10.1101/2022.02.25.481996
Select a neighboring publication to make it the new centre.